At Texas Institute for Neurological Disorders, clinical research has always been a major focus and our Research Department seeks to continue finding ways to offer patients other health care options not available through standard treatment. TIND Research is led by two board-certified neurologist physicians, Dr. Bharathy Sundaram and Dr. Easwar Sundaram, who have a combined experience of over 60 years in clinical neurology.
Many smaller or privately owned Neurology practices are unable to provide research opportunities to their patients for many reasons. Most research sites are conducted within a university setting or large research centers. Texas Institute for Neurological Disorders prides itself in being able to work with many different sponsors over the years to help collect data for the future treatment and diagnosis of many debilitating disorders.
TIND offers clinical trials for many neurological conditions for adult and pediatric patients including:
- Multiple Sclerosis
- Migraines
- Headaches
- Parkinson’s Disease
- Movement Disorders
- Spasticity
- Fibromyalgia
- Epilepsy
- Strokes
- Sleep Disorders
Key Benefits of Clinical Trial Participation
- Financial Benefits – avoiding office copays, sometimes having investigational product paid for
- Knowledge that the data being collected will help future patients with diagnosis and treatment options
- Increased exposure to allow greater access to ground breaking treatments available in the future
- Continues to allow the site access to potential new trials with investigational products
Current trials (not enrolling)
- Alithios: – Phase III Open Label Ofatumumab
- Gemini II – Phase III Tolebrutinib vs. Teriflunomide
- PASS – Phase IV Long Term Lemtrada Observational
Current trials (enrolling)
- FENTrepid: Phase III PPMS Fenebrutinib vs Ocrelizumab
- FENHance: Phase III RRMS Fenebrutinib vs. Aubagio
- Gavotte: Phase III PPMS Ocrelizumab vs. High Dose Ocrelizumab
- OMB157GUS12 Phase III Ofatumumab response to COVID-19
- OMB157GUS16 Phase III Ofatumumab response to Flu Vaccine
- Vercise – Registry Deep Brain Stimulation Study – Boston Scientific
- NM201 – Phase III NM3107 for Parkinsons Disease
- Direction – Phase III Dysport vs Botox for Upper Limb Spasticity post Stroke
- Intuition – Virtual Data Collection for patients with Mild Cognitive Impairment and Alzheimers
- BHV3000-315: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents > 6 to < 18 years of age
Brain Health Study: Now Enrolling!
Upcoming trials (will be enrolling soon)
- NM101 – Phase II NM3107 for Alzheimers Disease
- TrueBinding – Phase II for Ischemic Stroke
- R3918-MG-2018: A Phase III Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE)
- VP-VEC-162-3502: A Phase III multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)
To sign up for or learn more about research study opportunities at TIND, please contact our research team:
Laurie Jarvis
Clinical Research Manager
8 years of clinical research experience
ljarvis@texasneurologyinstitute.com
(903) 891-5141 ext. 4358
